Related Experiment Video
Updated: May 31, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Future directions in renal cell carcinoma: 2011 and beyond
Daniel C Cho1, Michael B Atkins
1Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. dcho1@bidmc.harvard.edu
Hematology/Oncology Clinics of North America
|July 19, 2011
Summary
Recent advances in renal cancer therapy have shifted from cytokine treatments to targeted and antiangiogenic agents for advanced renal cell carcinoma (RCC). Further innovations are needed to improve patient outcomes.
Area of Science:
- Oncology
- Nephrology
- Pharmacology
Background:
- The treatment of advanced renal cell carcinoma (RCC) has evolved significantly.
- Cytokine-based therapies have largely been replaced by newer treatment modalities.
- Molecularly targeted and antiangiogenic agents are now standard care for advanced RCC.
Purpose of the Study:
- To review the current therapeutic landscape for advanced renal cell carcinoma (RCC).
- To discuss challenges and innovations in RCC treatment.
- To identify potential improvements in therapeutic outcomes for RCC patients.
Main Methods:
- Literature review of recent advancements in RCC therapy.
- Analysis of the role of molecularly targeted and antiangiogenic agents.
- Discussion of clinical challenges and future research directions.
Main Results:
- Molecularly targeted and antiangiogenic agents represent the current standard of care for advanced RCC.
- While significant progress has been made, substantial room for improvement remains.
- Ongoing research focuses on overcoming therapeutic challenges and enhancing patient outcomes.
Conclusions:
- The therapeutic strategy for advanced renal cell carcinoma (RCC) has dramatically changed.
- Despite advances, further innovations are crucial for improving patient care and outcomes.
- Addressing current challenges is essential for future progress in RCC treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:20The Retinoblastoma Gene
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...